Coronavirus COVID-19 IgM ELISA Assay Kit


The Coronavirus COVID-19 IgM ELISA Assay Kit is used for the qualitative detection of novel coronavirus infected pneumonia cases, suspected clustering cases, and other new coronaviruses in serum samples (COVID-19) through measurement of the COVID-19 IgM antibody. It is a serological plate-based assay technique designed for detecting and quantifying substances such as peptides, proteins, antibodies and hormones. This test is not the same as PCR or Rapid Test. The Coronavirus COVID-19 IgM ELISA Assay Kit is for Research Use Only (RUO) in the USA, CE-Marked.

Coronavirus COVID-19 IgM ELISA Assay Kit

Coronavirus COVID-19 IgM ELISA Assay Kit was developed and manufactured in the US

Size: 1×96 wells
Sensitivity: Cut-off control
Incubation Time: 1 Hour, 20 minutes
Sample Type: Serum
Species Sample: Human
Sample Size: 20 µL
Alternative Names: Serology, Coronavirus, COVID-19, Corona, Serological
RUO, CE-Marked

Controls Included

Cross Reactivity

Panels were studied with a minimum of five confirmed disease state samples with this serology assay. No interference was observed for the following disease or infectious agents:

  • Anti-influenza A
  • Anti-influenza B
  • Hepatitis C (HCV)
  • Antinuclear Antibodies (ANA)
  • Respiratory Syncytial (RSV)

Assay Principle

The COVID-19 IgM ELISA Assay Kit is designed, developed, and produced for the qualitative measurement of the COVID-19 IgM antibody in serum samples. This COVID-19 serology ELISA assay utilizes the microplate based enzyme immunoassay technique.

Assay controls and samples, as well as the biotinylated COVID-19 specific peptide antigens are added to the microtiter wells of a microplate that was coated with a anti-human IgM specific antibody. After the first incubation period, the unbound protein matrix is removed with a subsequent washing step. A horseradish peroxidase (HRP) labeled streptavidin is added to each well. After an incubation period, an immunocomplex of ” Anti-hIgM antibody – human nCoV IgM antibody – HRP labeled COVID-19 antigen” is formed if there is novel coronavirus IgM antibody present in the tested materials. The unbound tracer antibody is removed by the subsequent washing step. HRP-labeled COVID-19 antigen tracer bound to the well is then incubated with a substrate solution in a timed reaction and then measured in a spectrophotometric microplate reader. The enzymatic activity of the tracer antibody bound to the coronoavirus IgM on the wall of the microtiter well is proportional to the amount of the coronavirus IgM antibody level in the tested material.

Products Related to Coronavirus COVID-19 IgM ELISA Assay

Coronavirus COVID-19 IgG ELISA Assay Kit

COVID-19 Flyer and Information

Additional Information

Assay Background

2019 novel coronavirus (COVID-19) is a single-stranded RNA coronavirus. Comparisons of the genetic sequences of is virus have shown similarities to SARS-CoV and bat coronaviruses. In humans, coronaviruses cause respiratory infections. Coronaviruses are composed of several proteins including the spike (S), envelope (E), membrane (M), and nucleocapsid (N). Results suggest that the spike protein retains sufficient affinity to the Angiotensin converting enzyme 2 (ACE2) receptor to use it as a mechanism of cell entry. Human to human transmission of coronaviruses is primarily thought to occur among close contacts via respiratory droplets generated by sneezing and coughing. IgM is the first immunoglobulin to be produced in response to an antigen and will be primarily detectable during the early onset of the disease.





The following papers utilize the Novel Coronavirus COVID-19 IgG or IgM ELISA Kits:

Jaddaoui, IE., Allali, M., Raoui, S., et al. A review on current diagnostic techniques for COVID-19. Expert Review of Molecular Diagnostics. (2021) 21:2, 141-160.

Datta M, Singh DD, Naqvi AR. Molecular Diagnostic tools for the Detection of SARS-CoV-2. Int Reb Immunol. 2021;40:143-156

Verma, N., Patel, D., Pandya, A. Emerging diagnostic tools for detection of COVID-19 and perspective. Biomedical Microdevices (2020)

Gudbjartsson, D. F., Norddahl, G. L., Melsted, P., Gunnarsdottir, K., Holm, H., Eythorsson, E., . . . Stefansson, K. (2020). Humoral Immune Response to SARS-CoV-2 in Iceland. New England Journal of Medicine. doi:10.1056/nejmoa2026116

Ahn JY, Sohn Y, Lee SH, et al. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea. J Korean Med Sci. 2020;35(14):e149. Published 2020 Apr 13. doi:10.3346/jkms.2020.35.e149

Ambroise Pare Hospital, Evaluation report of the EDI test at Ambroise Paré Hospital. Assistance Publique Hospitaux de Parix. Published 2020 May 14.

Margo Egger, et al. Comparison of the Elecsys® Anti-SARS-CoV-2 immunoassay with the EDITM enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma. Clinica Chimica Acta. Published 2020 May 28. doi/10.1016/j.cca.2020.05.049

Renata Varnaite, et al. Expansion of SARS-CoV-2-specific Antibody-secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients. BioRXiv. Published 2020 May 29. doi/10.1101/2020.05.28.118729

Christian Bundschuh et al. Evaluation of the EDI enzyme linked immunosorbent assays for the detection of SARS-CoV-2 IgM and IgG antibodies in human plasma. Clinica Chimica Acta. Published 2020 June 8.

Alexander Krüttgen et al. Comparison of four new commercial serologic assays for determination of SARS-CoV-2 IgG. Journal of Clinical Virology. 2020;128:104394. Published 2020 Apr 22. doi:10.1016/2020.104394